Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Metrics to compare | VKTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVKTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −72.0x | −2.0x | −0.6x | |
PEG Ratio | 31.94 | −0.03 | 0.00 | |
Price/Book | 7.8x | 0.6x | 2.6x | |
Price / LTM Sales | - | 25.1x | 3.2x | |
Upside (Analyst Target) | 74.2% | 200.0% | 47.5% | |
Fair Value Upside | Unlock | 3.3% | 6.7% | Unlock |